Skip to main content

Table 3 Matched-pair analysis for continuous variables

From: Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation

Variable PTLD mean Non-PTLD mean Mean difference of Non-PTLD minus PTLD p valuea Standard error of mean difference
Survival after Tx in years 7.74 9.98 2.24 0.004 0.72
PTLD-free survival in years 3.99 9.98 5.99 <0.001 0.76
Number of subsequent re-transplants 0.17 0.17 0.00 1.000 0.10
CIT in minutes 658.07 627.07 −31.00 0.756 99.05
BMI in kg/m2 20.05 20.13 0.09 0.890 0.62
Number of episodes of graft rejection 0.71 1.17 0.46 0.118 0.29
Number of episodes of EBV de novo infections or reactivations 0.50 0.50 0.00 1.000 0.15
Number of episodes of CMV de novo infections or reactivations 1.47 0.75 −0.72 0.042 0.34
Duration of pre-Tx dialysis in years 4.02 4.65 0.63 0.561 1.06
Number of HLA A locus recipient-donor mismatches 0.76 0.71 −0.06 0.791 0.22
Number of HLA B locus recipient-donor mismatches 1.12 1.06 −0.06 0.805 0.23
Number of HLA DR locus recipient-donor mismatches 0.94 1.06 0.12 0.431 0.15
Overall number of HLA recipient-donor mismatches 2.82 2.82 0.00 1.000 0.51
Daily dose of tacrolimus in mgb after Tx 3.74 1.62 −2.12 0.052 1.05
Blood level of tacrolimus in ng/mlb after Tx 9.97 8.13 −1.83 0.734 4.69
Daily dose of ciclosporine in mgb after Tx 176.17 183.06 6.89 0.832 32.24
C0 blood level of ciclosporine in μg/lb after Tx 218.46 195.91 −22.55 0.230 17.63
C2 blood level of ciclosporine in μg/lb after Tx 1183.0 1168.5 −14.5 0.909 100.5
Daily dose of MMF in mg afterb after Tx 545.00 551.67 6.67 0.967 161.43
Daily dose of prednisolone in mgb after Tx 11.13 10.99 −0.14 0.916 1.31
Daily dose of sirolimus inb after Tx 0.06 0.06 0.00 1.000 0.08
Daily dose of everolimus in mgb after Tx 0.06 0.14 0.08 0.585 0.15
Daily dose of azathioprine in mgb after Tx 2.08 2.78 0.69 0.160 0.48
Tacrolimus treatment in months c 12.47 15.62 3.15 0.596 5.87
Tacrolimus treatment in % of time of immunosuppressionc 46.87 33.45 −13.42 0.231 11.00
Ciclosporine treatment in monthsc 27.16 25.58 −1.58 0.737 4.67
Ciclosporine treatment in % of time of immunosuppressionc 46.25 59.70 13.45 0.180 9.83
CNI-free treatment in monthsc 6.96 5.29 −1.67 0.628 3.41
CNI-free treatment in % of time of immunosuppressionc 7.81 6.69 −1.11 0.803 4.42
  1. Shown are the results of univariable matched-pair analysis for continuous variables
  2. aPaired t test
  3. bAt hospital discharge
  4. cUntil PTLD diagnosis or equivalent date in the non-PTLD group)
  5. Tx transplantation, CIT cold ischemic time, BMI body mass index, EBV Epstein-Barr virus, CMV cytomegalovirus, HLA human leukocyte antigen, C0 trough blood level, C2 blood level 2 hours after oral intake, MMF mycophenolat mofetil, CNI calcineurin inhibitor